Oyster Point Pharmaceuticals

About:

Oyster is a clinical stage pharmaceutical company focused on the discovery development & commercialization .

Website: https://oysterpointrx.com/

Twitter/X: oysterpointrx

Top Investors: New Enterprise Associates, Invus, Vida Ventures, Versant Ventures, Flying L Partners

Description:

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence. OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).